{"prompt": "['Protocol VX18-445-109, Version 1.0', 'Page 40 of 60', 'Female subjects should not nurse a child during the period starting from the first dose of', 'study drug until 90 days after the last dose of study drug.', 'For male subjects with a female partner of childbearing potential, the couple should not plan', 'to become pregnant during the study or within 90 days after the last dose of study drug, with', 'the exception of couples who plan to become pregnant by artificial insemination using sperm', 'banked by the male subject before the first dose of study drug or sperm from another source.', '11.5.7.2', 'Pregnancy', 'Subjects will be counseled to inform the investigator of any pregnancy that occurs during study', 'treatment and for 90 days after the last dose of study drug.', 'If a female subject becomes pregnant during study participation, study drug will be permanently', 'discontinued immediately. The investigator will notify the medical monitor and Vertex GPS', \"within 24 hours of the site's knowledge of the subject's (or partner's) pregnancy using the\", 'Pregnancy Information Collection Form. Male subjects with female partners who become', 'pregnant during the study must use a male condom to avoid exposure of a potential embryo or', 'fetus to study drug via the seminal fluid.', 'If confirmed to be on active drug, the subject or partner will be followed until the end of the', 'pregnancy and the infant will be followed for 1 year after the birth, provided informed consent', '(and assent, as applicable) is obtained. A separate ICF will be provided to explain these', 'follow-up activities. Pregnancy itself does not constitute an AE.', '12', 'STATISTICAL AND ANALYTICAL PLANS', 'This section presents a summary of the planned analyses for this protocol. Statistical analysis', 'details will be provided in the statistical analysis plan (SAP), which will be finalized before the', 'clinical data lock for the study and treatment unblinding.', '12.1', 'Sample Size and Power', 'Up to approximately 158 subjects will be enrolled and randomized (1:1) to the', 'VX-445/TEZ/IVA group or the TEZ/IVA group. Information regarding the powering of primary', 'and key secondary endpoints is provided below.', 'Power for Primary Efficacy Endpoint', 'The primary efficacy endpoint is the absolute change in CFQ-R respiratory domain score from', 'baseline through Week 24. The primary null hypothesis to be tested is that the mean absolute', 'change in CFQ-R respiratory domain score from baseline is the same for the 2 treatment groups,', 'VX-445/TEZ/IVA and TEZ/IVA. The null hypothesis will be tested at a 2-sided significance', 'level of 0.05.', 'Assuming a within-group SD of 18 and a treatment difference of 10 between VX-445/TEZ/IVA', 'and TEZ/IVA, a sample size of 71 subjects completing the Treatment Period in each group for a', 'total of 142 subjects will have approximately 90% power for the CFQ-R respiratory domain', 'score hypothesis testing, based on a 2-sample t-test at a significance level of 0.05 (2-sided).', 'Assuming a 10% dropout rate, up to approximately 158 subjects will be enrolled.', 'Vertex Pharmaceuticals Incorporated']['Protocol VX18-445-109, Version 1.0', 'Page 41 of 60', 'Power for Key Secondary Endpoint', 'The key secondary endpoint is the absolute change in ppFEV1 from baseline through Week 24.', 'Assuming a within-group SD of 7 percentage points and a treatment difference of 5 between', 'VX-445/TEZ/IVA and TEZ/IVA, a sample size of 71 subjects completing the Treatment Period', 'in each group for a total of 142 subjects will have approximately 98% power for the ppFEV1', 'hypothesis testing, based on a 2-sample t-test at a significant level of 0.05 (2-sided). Assuming a', '10% dropout rate, approximately 158 subjects will be enrolled.', 'All power calculations were based on EAST software Version 6.4.', '12.2', 'Analysis Sets', 'The following analysis sets are defined: All Subjects Set, Full Analysis Set (FAS), and Safety', 'Set. Additional analysis sets related to the Run-in Period will be defined in the SAP, as', 'appropriate.', 'The All Subjects Set will include all subjects who were randomized or received at least 1 dose', 'of study drug. This analysis set will be used for all individual subject data listings and disposition', 'summary tables, unless otherwise specified.', 'The FAS will include all randomized subjects who carry the intended CFTR allele mutation and', 'receive at least 1 dose of study drug in the Treatment Period. The FAS will be used to summarize', 'subject demographics and baseline characteristics, and for all efficacy analyses in which subjects', 'will be analyzed according to their randomized treatment group, unless otherwise specified.', 'The Safety Set for the Treatment Period will include all subjects who receive at least 1 dose of', 'study drug in the Treatment Period. This safety set will be used for all safety analyses in which', 'subjects will be analyzed according to the treatment they receive, unless otherwise specified.', 'The Safety Set for the Run-in Period will include all subjects who received at least 1 dose of', 'study drug in the Run-in Period.', '12.3', 'Statistical Analysis', '12.3.1', 'General Considerations', 'Continuous variables will be summarized using the following descriptive summary statistics:', 'the number of subjects (n), mean, SD, median, minimum value (min), and maximum value', '(max).', 'Categorical variables will be summarized using counts and percentages.', 'The baseline value, unless otherwise specified, will be defined as the most recent non-missing', 'measurement (scheduled or unscheduled) collected before the first dose of study drug in the', 'Treatment Period (i.e., the Day 1 Visit). For ECG, baseline will be defined as the most recent', 'pretreatment measurement (or the average of triplicate measurements, if the most recent', 'pretreatment measurement is obtained in triplicate) before the first dose of study drug in the', 'Treatment Period (i.e., the Day 1 Visit).', 'Absolute change from baseline will be calculated as post-baseline value - baseline value.', 'The Treatment-emergent (TE) Period for the Run-in Period will be from the first dose of', 'study drug in the Run-in Period to (1) the first dose of study drug in the Treatment Period for', 'subjects who complete the Run-in Period and continue to the Treatment Period, or (2) 28 days', 'Vertex Pharmaceuticals Incorporated']\n\n###\n\n", "completion": "END"}